Galderma is the leading company solely dedicated to the human body’s largest organ: the skin. We are strategically positioned in resilient, highly attractive and consumer-focused sub-segments of injectable aesthetics, dermatological skincare and therapeutic dermatology.
Our unique Integrated Dermatology Strategy is the driving force behind our growth. It is our differentiating factor, and underscores our ambition to advance our category leadership in dermatology.
We work in close partnership with healthcare professionals to earn their trust and to meet individual consumer and patient needs, with superior outcomes.
KEY FACTS ABOUT GALDERMA
4.410 B USD
2024 net sales
4
manufacturing sites
330
million units produced a year
7,000+
employees worldwide
770+
clinical trials funded across 30+ countries since 2019
250+
major regulatory approvals since 2019
10,000+
training events hosted via the Global Aesthetic Injector Network (GAIN) program in 2024
110,000+
Healthcare professionals engaged in Global Aesthetic Injector Network (GAIN) events
Find out about our leadership team
A timeline of our history
1981
Foundation of Galderma as a joint venture between L’Oréal and Nestlé
Following the invention of the first Cetaphil formulation in 1947
1984
Galderma discovers Adapalene
1986
First commercial operations
1995
Launch of Differin for acne treatment
2000
Opening of our production site in Baie d’Urfé, Canada
2001
Licensing agreement for Metvix (Skin cancer)
2004
Opening of our production site in Hortolândia, Brazil
2007
Launch of Differin 0.3%
2008
Launch of Epiduo
2009
Launch of Azzalure and Restylane Injector
